

## **Quality Standards Advisory Committee 1**

## Preterm labour and birth post-consultation meeting

## Minutes of the meeting held on 07 July 2016 at the NICE offices in Manchester

	Standing Quality Standards Advisory Committee (QSAC) members
Attendees	Bee Wee (Chair) Ivan Benett, Gita Bhutani, Amanda De La Motte, Phillip Dick, Phyllis Dunn, Sunil Gupta, Steve Hajioff, Ian Manifold, Gavin
	Maxwell, Teresa Middleton, Ian Reekie, Hazel Trender, Alyson Whitmarsh, Hugo Van Woerden, Jane Worsley, Arnold Zermansky
	Specialist committee members
	Sam Oddie, Jane Plumb, Meekai To, Louise- Weaver-Lowe,
	NICE staff
	Nick Baillie (NB), Stephanie Birtles (SB), Sabina Keane (SK), Alaster Rutherford (AR), Julia Sus (JS)
	Topic expert advisers
	None
	Standing Quality Standards Advisory Committee (QSAC) members
Apologies	Helen Bromley

Agenda item	Discussions and decisions	Actions
1. Welcome, introductions and plan for the day (private session)	The Chair welcomed the attendees and the Quality Standards Advisory Committee (QSAC) members introduced themselves.  The Chair informed the committee of the apologies and reviewed the agenda for the day.	
2. Welcome and code of conduct for members of the public attending the meeting	The Chair welcomed the public observers and reminded them of the code of conduct that they were required to follow. It was stressed that they were not able to contribute to the meeting but were there to observe only. They were also reminded that the committee is independent and advisory therefore the discussions and decisions made today may change following final validation by NICE's guidance executive.	



Agenda item	Discussions and decisions	Actions
(public session)		
3. Committee business (public session)	Declarations of interest  The Chair asked standing QSAC members to declare any interests that were either in addition to their previously submitted declaration or specific to the topic(s) under consideration at the meeting today. The Chair asked the specialist committee members to declare all interests. The following interests were declared:	
	<ul> <li>Specialist committee members</li> <li>Jane Plumb- Spokesperson for Group B Strep Support.</li> <li>Sam Oddie- Author to a review paper advocating increased usage of antenatal magnesium to reduce cerebral palsy in preterm infants. 'Antenatal magnesium sulfate: Neuro-protection for preterm infants. Arch Dis Child Fetal Neonatal Ed. 2015 Apr 20'</li> </ul>	
	Minutes from the last meeting  The committee reviewed the minutes of the last meeting held on 02.06.16 and confirmed them as an accurate record.	
4. QSAC updates	None	
5. Recap of prioritisation exercise	SB and SK presented a recap of the areas for quality improvement discussed at the first QSAC meeting for preterm labour and birth:  At the first QSAC meeting on 4 February 2016 the QSAC agreed that the following areas for quality	
	improvement should be progressed for further consideration by the NICE team for potential inclusion in the draft quality standard:	
	Non- prioritised:  Identifying infection in women with P-PROM  Diagnosing preterm labour for women with intact membranes  Timing of cord clamping for preterm babies (born vaginally or by caesarean section)	
	Prioritised :  Information and support  Prophylactic vaginal progesterone and prophylactic cervical cerclage  Tocolysis	



Agenda item	Discussions and decisions	Actions
	<ul> <li>Maternal corticosteroids</li> <li>Magnesium sulphate for neuroprotection</li> <li>The full rationale for these decisions is available in the prioritisation meeting minutes which can be found here: <a href="https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Quality-Standards-Advisory-Committee/QSAC1/QSAC-1-minutes-Feb-16.pdf">https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Quality-Standards-Advisory-Committee/QSAC1/QSAC-1-minutes-Feb-16.pdf</a>.</li> </ul>	
5.2 and 5.3 Presentation and discussion of stakeholder feedback and key themes/issues raised	SK presented the committee with a report summarising consultation comments received on preterm labour and birth. The committee was reminded that this document provided a high level summary of the consultation comments, prepared by the NICE quality standards team, and was intended to provide an initial basis for discussion. The committee was therefore reminded to also refer to the full list of consultation comments provided throughout the meeting.  The committee was informed that comments which may result in changes to the quality standard had been highlighted in the summary report. Those comments which suggested changes which were outside of the process, were not included in the summary but had been included within the full list of comments, which was within the appendix. These included the following types of comment:  • Relating to source guidance recommendations • Suggestions for non-accredited source guidance • Request to broaden statements out of scope • Inclusion of overarching thresholds or targets • Requests to include large volumes of supporting information, provision of detailed implementation advice • General comments on role and purpose of quality standards • Requests to change NICE templates	
5.4 Discussion and agreement of final	The committee discussed each statement in turn and agreed upon a revised set. These statements are not final and may change as a result of the editorial and validation processes.	
statements	Draft Quality Statement 1: Women at increased risk of preterm labour are given information about the potential signs and symptoms.  The committee discussed feedback from stakeholders about expanding the inclusion criteria for the group of women who are given information about potential signs and symptoms of preterm labour and birth to ensure all women at risk are included. The committee agreed that the specification of the population	NICE team to progress the statement and expand definition to reflect population of all women at risk of preterm labour and birth with



Agenda item	Discussions and decisions	Actions
	should be expanded in the definition and rationale for clarification. The committee suggested including names of charities that women at risk of preterm labour and birth could contact in case they need more information but it was agreed that no specific charities should be included as the list would not be exhaustive and may unintentionally cause charities not on the list to be overlooked.	SCM input.
	Draft Quality Statement 2: Prophylactic vaginal progesterone and prophylactic cervical cerclage (statement wording to be developed)  Following the consultation, committee members discussed stakeholders' comments about prophylactic vaginal progesterone and prophylactic cervical cerclage treatments and agreed this is an area for quality improvement as this is related to prevention. The committee agreed that this should be an intervention focused statement which will drive improvement in the use of the treatments. The committee highlighted that depending on the ultrasound results women at risk of preterm labour should be offered prophylactic vaginal progesterone or prophylactic cervical cerclage with the benefits and risks of each of the procedures explained to them to ensure they make an informed choice about the treatment.  The committee agreed that there should be two measures in the statement. The committee agreed that this statement should drive improvement in the availability of the equipment and facilities in the hospitals to perform ultrasound and the above treatments.	NICE to progress a statement on prophylactic vaginal progesterone and prophylactic cervical cerclage based on recommendation 1.2.1 of NICE guideline NG25.
	Draft Quality Statement 3: Women who are having a planned preterm birth are given information about the risks and outcomes including the likelihood of the baby surviving.  The committee agreed that the statement is accurate and should be progressed. However, committee members raised issues with the definitions and agreed to work with the NICE team to expand on the rationale and specify the meaning of the terms planned, unplanned and suspected preterm labour to ensure clarity.	NICE team to progress a statement after amending the rationale.
	<ul> <li>Draft Quality Statement 4: Women in suspected preterm labour who are 29<sup>+6</sup> weeks pregnant or less are offered tocolysis, maternal corticosteroids and magnesium sulphate.</li> <li>The committee agreed that this statement should be progressed but the pregnancy population should be refined to state the specific timings to enable definition of the population. The wording of the statement will</li> </ul>	NICE team to progress a statement after amending the statement wording.



Agenda item	Discussions and decisions	Actions
	include the specific population for the intervention of administration of tocolysis, maternal corticosteroids and magnesium sulphate as potential components of a package of care, each needing to be clinically appropriate	
	<b>Draft Quality Statement 5:</b> Women between 30 and 33 <sup>+6</sup> weeks of pregnancy are offered maternal corticosteroids if they are in diagnosed preterm labour, are having a planned preterm birth, or have preterm prelabour rupture of membranes (P-PROM).	NICE team to progress the statement.
	The committee discussed the rationale wording to consider the comments made at consultation and if changes were required. The committee agreed that this statement should be progressed with no changes.	
	Additional areas suggested by stakeholders	
	The committee discussed the following additional areas that were suggested by stakeholders:	
	A number of suggestions were received from stakeholders about possible additional areas that are not in the scope of this quality standard. The committee discussed them in turn, but agreed that none of the suggested areas should be progressed as new statements, either because the areas were felt to be covered by other quality standards referred or in development, or because there were no source guideline recommendations.	
	<ol> <li>Early antenatal care and continuity of care from the same midwife</li> <li>Appropriate monitoring</li> <li>Delayed cord clamping</li> <li>Information on cervical length assessments</li> <li>Administration of progesterone</li> <li>Use of cervical cerclage.</li> </ol>	
6. Overarching outcomes	The NICE team explained that the quality standard would describe overarching outcomes that could be improved by implementing a quality standard on preterm labour and birth. It was agreed that the committee would contribute suggestions as the quality standard was developed.	
7. Equality and diversity	The NICE team explained that equality and diversity considerations should inform the development of the quality standard, and asked the committee to consider any relevant issues. It was agreed that the committee would contribute suggestions as the quality standard was developed.	



Agenda item	Discussions and decisions	Actions
8. Next steps and timescales (part 1 – open session)	SK outlined what will happen following the meeting and key dates for the preterm labour and birth quality standard.	
9. Any other business (part 2 – Private session)	There were no items of AOB raised.  The Chair thanked the specialist committee members for their input into the development of this quality standard,  Date of next QSAC 1 meeting Thursday 1 September 2016	